MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLTX MoonLake Immunotherapeutics

Trading 06-29 13:48:34 EDT

20.05

+0.15

+0.75%

High20.14	Low19.70	Vol737.82K
Open20.07	D1 Closing19.90	Amplitude2.21%
Mkt Cap1.66B	Tradable Cap980.11M	Total Shares82.62M
T/O14.74M	T/O Rate1.51%	Tradable Shares48.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":20.05,"timestamp":1782755310252,"preClose":19.9,"halted":0,"volume":737815,"delay":0,"changeRate":0.0075376884422111625,"floatShares":48883100,"shares":82615400,"eps":-3.869523,"marketStatus":"Trading","change":0.15,"latestTime":"06-29 13:48:34 EDT","open":20.07,"high":20.14,"low":19.7,"amount":14739254.997869998,"amplitude":0.022111,"askPrice":20.07,"askSize":212,"bidPrice":20.04,"bidSize":21,"shortable":3,"etf":0,"ttmEps":-3.869523,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782763200000},"marketStatusCode":2,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":19.9,"preHourTrading":{"tag":"盘前","latestPrice":20,"preClose":19.9,"latestTime":"09:02 EDT","volume":414,"amount":8441.08326,"timestamp":1782738142121,"change":0.1,"changeRate":0.005025,"amplitude":0.046894},"postHourTrading":{"tag":"盘后","latestPrice":20.25,"preClose":19.9,"latestTime":"19:46 EDT","volume":27588,"amount":549094.3199,"timestamp":1782517606490,"change":0.35,"changeRate":0.017588,"amplitude":0.017588},"volumeRatio":0.39966,"impliedVol":1.0528,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/MLTX/wiki","defaultTab":"wiki","newsList":[{"id":"2646887400","title":"MoonLake Immunotherapeutics Announces $200 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2646887400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646887400?lang=en_us&edition=fundamental","pubTime":"2026-06-25 18:45","pubTimestamp":1782384342,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics ( ($MLTX) ) just unveiled an announcement. On June 23, 2026, MoonLake Immunotherapeutics entered into an underwriting a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moonlake-immunotherapeutics-announces-200-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moonlake-immunotherapeutics-announces-200-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645816327","title":"Moonlake Immunotherapeutics Slides After $200 Mln Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2645816327","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645816327?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:41","pubTimestamp":1782308473,"startTime":"0","endTime":"0","summary":"BUZZ-MoonLake Immunotherapeutics slides after $200 mln share sale** Swiss biotech MoonLake Immunotherapeutics'MLTX.Oshares down 9.9% to $19.12 early Weds after $200 mln follow-on priced** MLTX late Tu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nL6N42W0UY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645003897","title":"H.C. Wainwright Remains a Buy on MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645003897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645003897?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:35","pubTimestamp":1782300954,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on MoonLake Immunotherapeutics today and set a price target of $45.00. According to T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645486616","title":"BRIEF-Moonlake Prices Offering Of 9 Million Class A Shares At $20/Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2645486616","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645486616?lang=en_us&edition=fundamental","pubTime":"2026-06-24 11:09","pubTimestamp":1782270566,"startTime":"0","endTime":"0","summary":"BRIEF-Moonlake Prices Offering Of 9 Million Class A Shares At $20/ShareJune 23 (Reuters) - MoonLake Immunotherapeutics MLTX.O:MOONLAKE IMMUNOTHERAPEUTICS ANNOUNCES PRICING OF UPSIZED $200 MILLION PUBL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA8WQMLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645386615","title":"MoonLake Immunotherapeutics prices upsized public offering at USD 200 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2645386615","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645386615?lang=en_us&edition=fundamental","pubTime":"2026-06-24 11:08","pubTimestamp":1782270523,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics priced an upsized public offering expected to raise about USD 200 million in gross proceeds.Deal includes 9,000,000 Class A ordinary shares priced at USD 20 per share.Also includes pre-funded warrants for up to 1,000,000 Class A ordinary shares priced at USD 19.9999, exercisable immediately.Underwriters hold a 30-day option to buy up to 1,500,000 additional Class A ordinary shares at the offering price.Proceeds earmarked for development, pre-commercialization, commercialization of sonelokimab, if approved, plus general corporate purposes.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL6jMNGm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","LU2210150020.SGD","BK4112","SG9999014021.USD","SG9999014039.USD","LU2095319765.USD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","MLTX","BK4139","NDAQ","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645866151","title":"MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645866151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645866151?lang=en_us&edition=fundamental","pubTime":"2026-06-24 11:08","pubTimestamp":1782270507,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA8WQMLW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645286615","title":"MoonLake: Prices Offering of 9 Mln Class a Shares at $20 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2645286615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645286615?lang=en_us&edition=fundamental","pubTime":"2026-06-24 11:08","pubTimestamp":1782270507,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA8WQMLW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859563","title":"MoonLake CFO Matthias Bodenstedt sells 39,120 shares for $862,205.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859563","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859563?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:01","pubTimestamp":1782244910,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 39,120 Class A ordinary shares on June 22, 2026.Weighted average sale price USD 22.04 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL74K4yk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MoonLake CFO Matthias Bodenstedt sells 39,120 shares for $862,205.60","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645070851","title":"MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2645070851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645070851?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:17","pubTimestamp":1782159469,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) announced a proposed public offering of $150M of its Class A ordinary shares and, in lieu of Class A ordinary sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-announces-150m-offering-of-class-a-ordinary-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-immunotherapeutics-announces-150m-offering-of-class-a-ordinary-shares-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645807790","title":"MoonLake Immunotherapeutics Shares Fall About 4% to $21.28 After the Bell Following Public Offering Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2645807790","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645807790?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:04","pubTimestamp":1782158656,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL6N42U14V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077962","title":"MoonLake Immunotherapeutics plans USD 150 million follow-on share offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077962","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077962?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:01","pubTimestamp":1782158484,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics launched a follow-on public offering of USD 150 million of Class A ordinary shares.Some investors can choose pre-funded warrants in lieu of Class A ordinary shares.Underwriters have a 30-day option to buy up to an additional USD 22.5 million of Class A ordinary shares.Proceeds earmarked for development, pre-commercialization, commercial launch work for sonelokimab, if approved, and general corporate purposes.Leerink Partners, Guggenheim Securities, Cantor, LifeSci Capital named joint bookrunners.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDLPzv5T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2T93.GBP","LU2210149790.SGD","MNSH","SG9999014005.SGD","LU0314104364.USD","BK4207","MLTX","SG9999014039.USD","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4585","BK4588","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","LU2095319765.USD","SG9999014021.USD","BK4139","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645958077","title":"MoonLake Immunotherapeutics - Announces Proposed $150 Mln Public Offering of Class a Shares and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2645958077","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645958077?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:01","pubTimestamp":1782158460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA3RDJC6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645077938","title":"MoonLake Immunotherapeutics - Proceeds to Fund Sonelokimab Activities and General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2645077938","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645077938?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:01","pubTimestamp":1782158460,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nTUA3RDJC6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645071752","title":"MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2645071752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645071752?lang=en_us&edition=fundamental","pubTime":"2026-06-23 01:45","pubTimestamp":1782150323,"startTime":"0","endTime":"0","summary":"Following MoonLake Immunotherapeutics (MLTX)’ investor event focused on the development and commercialization of SLK in hidradenitis suppurativa, C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlakes-slk-has-blockbuster-potential-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlakes-slk-has-blockbuster-potential-says-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645624079","title":"Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN) and MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645624079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645624079?lang=en_us&edition=fundamental","pubTime":"2026-06-23 00:30","pubTimestamp":1782145813,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eledon Pharmaceuticals (ELDN) and MoonLake Immunothe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-eledon-pharmaceuticals-eldn-and-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LABU","LU0029874061.USD","MLTX","BK4139","ELDN","BK4585","HCSG","LU0128526141.USD","XLV","BK4581","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645218540","title":"MoonLake Shares Rise on Late-Stage Data for Hidradenitis Suppurativa Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645218540","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645218540?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:14","pubTimestamp":1782126840,"startTime":"0","endTime":"0","summary":"Shares of MoonLake Immunotherapeutics rose after the company said a late-stage trial of its treatment for moderate-to-severe hidradenitis suppurativa showed consistent and further improvement in all clinical scores at 52 weeks, compared with an earlier readout at 16 weeks.The stock climbed 22%, to $23.56, in premarket trading Monday. Through Friday's close, shares are up more than 60% since the beginning of the year, despite having fallen roughly 57% over the past 52 weeks.The biotechnology company said before the bell that the data supports the treatment's, sonelokimab, potential best-in-class and best-in-disease profile, with responses that are higher than those observed in trials of competing treatments.Chief Executive Jorge Santos da Silva said sonelokimab showed strength across most, if not all, metrics that matter in hidradenitis suppurativa. These include strong early efficacy, sustained and leading improvement over time, a consistent safety profile and convenience in dosing, it","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645012652","title":"MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2645012652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645012652?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:20","pubTimestamp":1782091259,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) announced the Week 52 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global prog...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-announces-week-52-results-of-phase-3-vela-1-vela-2-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-announces-week-52-results-of-phase-3-vela-1-vela-2-trials-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645016481","title":"MoonLake says Phase 3 VELA trials show sonelokimab hits 67% HiSCR75 at Week 52 in hidradenitis suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2645016481","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645016481?lang=en_us&edition=fundamental","pubTime":"2026-06-22 05:00","pubTimestamp":1782075620,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics released 52-week Phase 3 VELA results for sonelokimab in hidradenitis suppurativa, extending efficacy and safety seen earlier in the program.Patients maintained strong disease control over one year, with meaningful improvements in quality of life and pain versus baseline, with no new safety signals.Adolescent VELA-TEEN interim results were already reported through week 24, showing a rapid response with a safety profile consistent with adults.A Biologics License Application filing for hidradenitis suppurativa is expected at the end of September 2026, with an FDA filing decision expected by late November 2026.MoonLake scheduled an investor day for June 22, 2026 to present the final one-year dataset, label approach, commercialization plan, and key second-half 2026 catalysts.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nNDL5z9fBz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","SG9999014013.SGD","SG9999014039.USD","NDAQ","BK4139","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD","SG9999014005.SGD","MLTX","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210150020.SGD","BK4585","BK4112","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645164880","title":"MoonLake Announces Week 52 Results of Sonelokimab From Its Phase 3 Vela Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645164880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645164880?lang=en_us&edition=fundamental","pubTime":"2026-06-22 05:00","pubTimestamp":1782075601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nTUA6WKTSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644103034","title":"MoonLake CFO Matthias Bodenstedt sells $351,804 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644103034","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644103034?lang=en_us&edition=fundamental","pubTime":"2026-06-19 06:45","pubTimestamp":1781822756,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 17,876 Class A ordinary shares on June 17-18, 2026.Sales priced at USD 19.68 on June 17, USD 19.6 on June 18.Beneficial ownership fell to 1,154,555 Class A ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL7YsgCP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MoonLake CFO Matthias Bodenstedt sells $351,804 of common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":0.0359},{"period":"1month","weight":0.0809},{"period":"3month","weight":0.149},{"period":"6month","weight":0.4389},{"period":"1year","weight":-0.5792},{"period":"ytd","weight":0.5099}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.083781},{"month":3,"riseRate":0.666667,"avgChangeRate":0.033144},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.114037},{"month":5,"riseRate":0.5,"avgChangeRate":0.100872},{"month":6,"riseRate":0.833333,"avgChangeRate":0.152896},{"month":7,"riseRate":0.6,"avgChangeRate":0.073307},{"month":8,"riseRate":0.6,"avgChangeRate":0.090179},{"month":9,"riseRate":0.4,"avgChangeRate":-0.166769},{"month":10,"riseRate":0.6,"avgChangeRate":0.061028},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}